Clinical trial
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects…
NCT00382512 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00382512 |
|---|---|
| Title | A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis |
| Official title | A Randomized, Placebo-Controlled, Single-Blind, Parallel-Group Study to Evaluate the Effects of 12 Weekly Subcutaneous Doses of 1.0 mg/kg Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | Raptiva (efalizumab) |
| Enrollment | 60 |
| Start date | May 1, 2003 |
| First posted | Sep 29, 2006 |
| Last update posted | Sep 29, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: